- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Bristol Myers' Cobenfy performance called into question amid overall Q3 revenue beat | ||
| Do | Lonza rounds out Swiss ADC expansion's scope with mid-scale capabilities | ||
| Do | Kennedy's HHS relaxes enforcement on 6 popular wellness peptides | ||
| Do | Geron's Rytelo stumbles in phase 3 as Novartis gears up for post-JAK inhibitor blood cancer bid | ||
| 28.10. | 'Numbers speak for themselves': Biogen's Apellis buyout fuels best quarter since 2020 | ||
| 28.10. | Lilly combines global markets under new leadership role as 36-year veteran retires | ||
| 28.10. | After GSK's Q3 approval spate, Hibsago preps for 'concentrated' US hep B launch | ||
| 28.10. | Blue Matter 'turbocharges' global reach of comms agency Cognite with acquistion | ||
| 28.10. | GSK vows not to 'park crap on Page 41' in transparency push | ||
| 28.10. | Amgen hit with FDA warning letter for 'misleading' Vectibix promotion | ||
| 28.10. | Supernus shreds ADHD stigma with Olympic snowboarder Chloe Kim | ||
| 28.10. | Eversana combines forces with UK-based AI health economics research firm Estima in acquisition | ||
| 28.10. | Eli Lilly surges up diabetes reputation rankings to close in on Novo | ||
| 27.10. | Teva telegraphs 61 job cuts amid plans to close 'underutilized' New Jersey plant | ||
| 27.10. | Vanda eyes GLP-1 nausea indication with Nereus phase 3 win in hand | ||
| 27.10. | UCB's Bimzelx leads pharmna's Q3 drug ad spend, but who will take the annual prize? | ||
| 27.10. | Pfizer heads to FDA with phase 3 myeloma win for Elrexfio | ||
| 27.10. | Novartis CEO unfazed by high-profile clinical failures, maintains long-term revenue goal | ||
| 27.10. | WuXi AppTec bucks DOD uncertainty through Q3, lifting forecast for 2026 | ||
| 27.10. | Eli Lilly fends off Novo's legal bid to block GLP-1 marketing claims | ||
| 27.10. | Sun locks in first DTC spot for alopecia areata med Leqselvi | ||
| 27.10. | Regeneron lands $270M in renewed US supply pact for approved Ebola med Inmazeb | ||
| 26.10. | Pfizer's Talzenna combo moves up treatment line with new FDA nod in prostate cancer | ||
| 26.10. | ESMO: In sac-TMT's first global phase 3 win, Merck sees 'pretty consistent' data with China | ||
| 26.10. | Novartis' Rhapsido touts solid efficacy with industry-best safety data in RMS phase 3 reveal |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.